These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 35045694)

  • 1. T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial.
    Blixt L; Wullimann D; Aleman S; Lundin J; Chen P; Gao Y; Cuapio A; Akber M; Lange J; Rivera-Ballesteros O; Buggert M; Ljunggren HG; Hansson L; Österborg A
    Haematologica; 2022 Apr; 107(4):1000-1003. PubMed ID: 35045694
    [No Abstract]   [Full Text] [Related]  

  • 2. Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia.
    Herishanu Y; Avivi I; Levi S; Shefer G; Bronstein Y; Moshiashvili MM; Ziv T; Scarfò L; Perry C; Ghia P
    Blood Adv; 2022 Jan; 6(1):148-151. PubMed ID: 34614513
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.
    Molica S; Giannarelli D; Lentini M; Zappala D; Mannella A; Loiacono D; Gianfelici V; Panduri G; Gariani I; Minchella P; Talarico F; Levato L
    Chemotherapy; 2022; 67(2):91-95. PubMed ID: 34872098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
    Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Söderdahl G; Österborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgström E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin AC; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Loré K; Chen MS; Buggert M; Ljunggren HG; Ljungman P; Aleman S;
    EBioMedicine; 2021 Dec; 74():103705. PubMed ID: 34861491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia.
    Molica S; Tam C; Polliack A
    Hematol Oncol; 2022 Aug; 40(3):313-319. PubMed ID: 35304771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diminished T-cell immune responses to SARS-CoV-2 omicron variant after BNT162b2 vaccination.
    Jordan SC; Shin BH; Rodriguez E; Vo A; NorikoAmmerman ; Zhang R
    Immunol Lett; 2022 Aug; 248():123-125. PubMed ID: 35843362
    [No Abstract]   [Full Text] [Related]  

  • 7. Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia.
    da Cunha-Bang C; Kirkby NS; Friis-Hansen L; Niemann CU
    Leuk Lymphoma; 2022 Feb; 63(2):503-505. PubMed ID: 34727829
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
    Benjamini O; Rokach L; Itchaki G; Braester A; Shvidel L; Goldschmidt N; Shapira S; Dally N; Avigdor A; Rahav G; Lustig Y; Ben David SS; Fineman R; Paz A; Bairey O; Polliack A; Levy I; Tadmor T
    Haematologica; 2022 Mar; 107(3):625-634. PubMed ID: 34320789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273.
    Markewitz R; Pauli D; Dargvainiene J; Steinhagen K; Engel S; Herbst V; Zapf D; Krüger C; Sharifzadeh S; Schomburg B; Leypoldt F; Rupp J; Görg S; Junker R; Wandinger KP
    Clin Microbiol Infect; 2022 May; 28(5):701-709. PubMed ID: 34547457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
    Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
    Front Immunol; 2022; 13():846753. PubMed ID: 35309297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals.
    Cuapio A; Boulouis C; Filipovic I; Wullimann D; Kammann T; Parrot T; Chen P; Akber M; Gao Y; Hammer Q; Strunz B; Pérez Potti A; Rivera Ballesteros O; Lange J; Muvva JR; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Söderdahl G; Österborg A; Smith CIE; Bogdanovic G; Muschiol S; Hellgren F; Loré K; Sobkowiak MJ; Gabarrini G; Healy K; Sällberg Chen M; Alici E; Björkström NK; Buggert M; Ljungman P; Sandberg JK; Aleman S; Ljunggren HG
    Mol Med; 2022 Feb; 28(1):20. PubMed ID: 35135470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients.
    Zaleska J; Kwasnik P; Paziewska M; Purkot J; Szabelak A; Jurek M; Masny N; Dziatkiewicz I; Pronobis-Szczylik B; Piebiak A; Szymczyk A; Jarosz-Chudzik K; Bolkun L; Kozlowska K; Piszcz J; Subocz E; Halka J; Bator M; Kalicinska E; Wrobel T; Usnarska-Zubkiewicz L; Rybka J; Deren-Wagemann I; Szyca-Smieszniak M; Dybko J; Hus I; Pula B; Cichocka E; Rymko M; Zdunczyk D; Ziarkiewicz M; Basak GW; Bullinger L; Giannopoulos K
    Int J Cancer; 2023 Feb; 152(4):705-712. PubMed ID: 35830214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities.
    Trigueros M; Pradenas E; Palacín D; Muñoz-López F; Ávila-Nieto C; Trinité B; Bonet-Simó JM; Isnard M; Moreno N; Marfil S; Rovirosa C; Puig T; Grau E; Chamorro A; Martinez A; Toledo R; Font M; Ara J; Carrillo J; Mateu L; Blanco J; Clotet B; Prat N; Massanella M;
    Age Ageing; 2022 May; 51(5):. PubMed ID: 35595256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.
    Bagacean C; Letestu R; Al-Nawakil C; Brichler S; Lévy V; Sritharan N; Delmer A; Dartigeas C; Leblond V; Roos-Weil D; Tomowiak C; Merabet F; Béné MC; Clavert A; Chaoui D; Genet P; Guieze R; Laribi K; Drénou B; Willems L; Puppinck C; Legendre H; Troussard X; Malartre S; Cymbalista F; Michallet AS
    Blood Adv; 2022 Jan; 6(1):207-211. PubMed ID: 34844264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients.
    Bajwa HM; Novak F; Nilsson AC; Nielsen C; Holm DK; Østergaard K; Witt AH; Byg KE; Johansen IS; Mittl K; Rowles W; Zamvil SS; Bove R; Sabatino JJ; Sejbaek T
    Mult Scler Relat Disord; 2022 Apr; 60():103729. PubMed ID: 35334278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination.
    Gonzalez-Perez M; Montes-Casado M; Conde P; Cervera I; Baranda J; Berges-Buxeda MJ; Perez-Olmeda M; Sanchez-Tarjuelo R; Utrero-Rico A; Lozano-Ojalvo D; Torre D; Schwarz M; Guccione E; Camara C; Llópez-Carratalá MR; Gonzalez-Parra E; Portoles P; Ortiz A; Portoles J; Ochando J
    Front Immunol; 2022; 13():845882. PubMed ID: 35401504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Benda M; Mutschlechner B; Ulmer H; Grabher C; Severgnini L; Volgger A; Reimann P; Lang T; Atzl M; Huynh M; Gasser K; Petrausch U; Fraunberger P; Hartmann B; Winder T
    Br J Haematol; 2021 Nov; 195(4):523-531. PubMed ID: 34346068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients.
    Hurme A; Jalkanen P; Heroum J; Liedes O; Vara S; Melin M; Teräsjärvi J; He Q; Pöysti S; Hänninen A; Oksi J; Vuorinen T; Kantele A; Tähtinen PA; Ivaska L; Kakkola L; Lempainen J; Julkunen I
    Front Immunol; 2022; 13():869990. PubMed ID: 35529867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.